Madison Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Madison Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$5.85M	Buy	+14,522	New	+$6.73M	0.07%	157

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Madison Investment Advisors's VRTX Position: Q4 2024 in Review

Madison Investment Advisors opened a new position in Vertex Pharmaceuticals (VRTX) in Q4 2024: 14,522 shares worth $5.85M. The stake represents 0.07% of the portfolio and ranks #157 among its holdings.

1,562 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

Madison Investment Advisors held 14,522 shares of Vertex Pharmaceuticals worth $5.85M as of Q4 2024.
Vertex Pharmaceuticals was a new Madison Investment Advisors position in Q4 2024.
Vertex Pharmaceuticals made up 0.07% of Madison Investment Advisors's portfolio in Q4 2024, its #157 holding.
1,562 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Madison Investment Advisors's 13F filing for Q4 2024, filed 10 Feb 2025.